论文部分内容阅读
新目标治疗(Treating to New Targets,TNT)临床试验(Am Society of Hypertension 21st Annual Scientific Meeting and Exposition May16-20:2006)已经证明10001名病人稳定型冠心病用80mg阿托伐他汀的疗效较10mg/d的效果好。主要心血管事件在80mg/d组为8.7%,